ES2660210T3 - Derivados de indolcarboxamida y usos de los mismos - Google Patents
Derivados de indolcarboxamida y usos de los mismos Download PDFInfo
- Publication number
- ES2660210T3 ES2660210T3 ES13792084.9T ES13792084T ES2660210T3 ES 2660210 T3 ES2660210 T3 ES 2660210T3 ES 13792084 T ES13792084 T ES 13792084T ES 2660210 T3 ES2660210 T3 ES 2660210T3
- Authority
- ES
- Spain
- Prior art keywords
- indole
- carboxamide
- methylcyclohexyl
- dichloro
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- VFHUJFBEFDVZPJ-UHFFFAOYSA-N 1h-indole-2-carboxamide Chemical class C1=CC=C2NC(C(=O)N)=CC2=C1 VFHUJFBEFDVZPJ-UHFFFAOYSA-N 0.000 title description 15
- 150000001875 compounds Chemical class 0.000 claims abstract description 125
- -1 fluoro-substituted methyl Chemical group 0.000 claims abstract description 44
- 150000003839 salts Chemical class 0.000 claims abstract description 37
- 239000000460 chlorine Substances 0.000 claims abstract description 26
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 24
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229910052801 chlorine Inorganic materials 0.000 claims abstract description 13
- 125000001153 fluoro group Chemical group F* 0.000 claims abstract description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 9
- 239000001257 hydrogen Substances 0.000 claims abstract description 9
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 9
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims abstract description 8
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229910052794 bromium Inorganic materials 0.000 claims abstract description 8
- 125000001424 substituent group Chemical group 0.000 claims abstract description 8
- 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 claims abstract description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 6
- 125000005843 halogen group Chemical group 0.000 claims abstract description 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims abstract description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims abstract description 4
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims abstract description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 3
- 201000008827 tuberculosis Diseases 0.000 claims description 64
- 239000003814 drug Substances 0.000 claims description 39
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 30
- 229940079593 drug Drugs 0.000 claims description 27
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 21
- 238000011282 treatment Methods 0.000 claims description 19
- 201000010099 disease Diseases 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 15
- 208000035475 disorder Diseases 0.000 claims description 13
- UATYSFRIVIHVKL-UHFFFAOYSA-N n-(4,4-dimethylcyclohexyl)-4,6-difluoro-1h-indole-2-carboxamide Chemical compound C1CC(C)(C)CCC1NC(=O)C1=CC2=C(F)C=C(F)C=C2N1 UATYSFRIVIHVKL-UHFFFAOYSA-N 0.000 claims description 11
- 206010036790 Productive cough Diseases 0.000 claims description 10
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 claims description 10
- 208000024794 sputum Diseases 0.000 claims description 10
- 210000003802 sputum Anatomy 0.000 claims description 10
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 8
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 8
- 239000008177 pharmaceutical agent Substances 0.000 claims description 8
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 8
- 101150105572 mmpL3 gene Proteins 0.000 claims description 7
- 208000011580 syndromic disease Diseases 0.000 claims description 7
- TZJDUUVOCXUTRC-UHFFFAOYSA-N 4-chloro-6-fluoro-n-(4-methylcyclohexyl)-1h-indole-2-carboxamide Chemical compound C1CC(C)CCC1NC(=O)C1=CC2=C(Cl)C=C(F)C=C2N1 TZJDUUVOCXUTRC-UHFFFAOYSA-N 0.000 claims description 6
- XLRNTZFYUSYXJI-UHFFFAOYSA-N 6-chloro-4-fluoro-n-(4-methylcyclohexyl)-1h-indole-2-carboxamide Chemical compound C1CC(C)CCC1NC(=O)C1=CC2=C(F)C=C(Cl)C=C2N1 XLRNTZFYUSYXJI-UHFFFAOYSA-N 0.000 claims description 6
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 229960003350 isoniazid Drugs 0.000 claims description 6
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 claims description 6
- GOJWKIPRMJQHGL-UHFFFAOYSA-N n-(4-methylcyclohexyl)-4,6-bis(trifluoromethyl)-1h-indole-2-carboxamide Chemical compound C1CC(C)CCC1NC(=O)C1=CC2=C(C(F)(F)F)C=C(C(F)(F)F)C=C2N1 GOJWKIPRMJQHGL-UHFFFAOYSA-N 0.000 claims description 6
- 229960001225 rifampicin Drugs 0.000 claims description 6
- 238000002560 therapeutic procedure Methods 0.000 claims description 6
- VCOPTHOUUNAYKQ-WBTCAYNUSA-N (3s)-3,6-diamino-n-[[(2s,5s,8e,11s,15s)-15-amino-11-[(6r)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide;(3s)-3,6-diamino-n-[[(2s,5s,8 Chemical compound N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1.N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1 VCOPTHOUUNAYKQ-WBTCAYNUSA-N 0.000 claims description 5
- MKBJWANFYAYLQQ-MGPUTAFESA-N 6-anilino-4-methyl-n-[(1r,2s)-2-methylcyclohexyl]-1h-indole-2-carboxamide Chemical compound C[C@H]1CCCC[C@H]1NC(=O)C(NC1=C2)=CC1=C(C)C=C2NC1=CC=CC=C1 MKBJWANFYAYLQQ-MGPUTAFESA-N 0.000 claims description 5
- MQYZRHHCNOJKPH-IINYFYTJSA-N 6-bromo-4-methyl-n-[(1r,2s)-2-methylcyclohexyl]-1h-indole-2-carboxamide Chemical compound C[C@H]1CCCC[C@H]1NC(=O)C1=CC2=C(C)C=C(Br)C=C2N1 MQYZRHHCNOJKPH-IINYFYTJSA-N 0.000 claims description 5
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 claims description 5
- 108010065839 Capreomycin Proteins 0.000 claims description 5
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 claims description 5
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 claims description 5
- 229960004821 amikacin Drugs 0.000 claims description 5
- 229960004602 capreomycin Drugs 0.000 claims description 5
- 229960000285 ethambutol Drugs 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 229930027917 kanamycin Natural products 0.000 claims description 5
- 229960000318 kanamycin Drugs 0.000 claims description 5
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 5
- 229930182823 kanamycin A Natural products 0.000 claims description 5
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 claims description 5
- 229960003702 moxifloxacin Drugs 0.000 claims description 5
- 229960001699 ofloxacin Drugs 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 229960005206 pyrazinamide Drugs 0.000 claims description 5
- IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 claims description 5
- SMAJIEHQYVPQNY-UHFFFAOYSA-N 4,6-dimethyl-n-(2-propan-2-ylcyclohexyl)-1h-indole-2-carboxamide Chemical compound CC(C)C1CCCCC1NC(=O)C1=CC2=C(C)C=C(C)C=C2N1 SMAJIEHQYVPQNY-UHFFFAOYSA-N 0.000 claims description 4
- QOICDOWLCQCNEB-GXFFZTMASA-N 4-bromo-n-[(1r,2s)-2-methylcyclohexyl]-1h-indole-2-carboxamide Chemical compound C[C@H]1CCCC[C@H]1NC(=O)C1=CC2=C(Br)C=CC=C2N1 QOICDOWLCQCNEB-GXFFZTMASA-N 0.000 claims description 4
- KZESTTWXIGVGNF-SMDDNHRTSA-N 4-cyano-n-[(1r,2s)-2-methylcyclohexyl]-1h-indole-2-carboxamide Chemical compound C[C@H]1CCCC[C@H]1NC(=O)C1=CC2=C(C#N)C=CC=C2N1 KZESTTWXIGVGNF-SMDDNHRTSA-N 0.000 claims description 4
- VWMMXVYGWBSSHR-GXTWGEPZSA-N 4-methyl-n-[(1r,2s)-2-methylcyclohexyl]-1h-indole-2-carboxamide Chemical compound C[C@H]1CCCC[C@H]1NC(=O)C1=CC2=C(C)C=CC=C2N1 VWMMXVYGWBSSHR-GXTWGEPZSA-N 0.000 claims description 4
- SKSCZARSITZAMO-GXFFZTMASA-N 6-bromo-n-[(1r,2s)-2-methylcyclohexyl]-1h-indole-2-carboxamide Chemical compound C[C@H]1CCCC[C@H]1NC(=O)C1=CC2=CC=C(Br)C=C2N1 SKSCZARSITZAMO-GXFFZTMASA-N 0.000 claims description 4
- VTZOAVRVIGLSDH-UHFFFAOYSA-N 6-chloro-n-(4-methylcyclohexyl)-1h-indole-2-carboxamide Chemical compound C1CC(C)CCC1NC(=O)C1=CC2=CC=C(Cl)C=C2N1 VTZOAVRVIGLSDH-UHFFFAOYSA-N 0.000 claims description 4
- OEZQBGUPOJTHJJ-XHDPSFHLSA-N 6-cyano-4-methyl-n-[(1r,2s)-2-methylcyclohexyl]-1h-indole-2-carboxamide Chemical compound C[C@H]1CCCC[C@H]1NC(=O)C1=CC2=C(C)C=C(C#N)C=C2N1 OEZQBGUPOJTHJJ-XHDPSFHLSA-N 0.000 claims description 4
- WVMIUZBFRMIPHI-SMDDNHRTSA-N 6-cyano-n-[(1r,2s)-2-methylcyclohexyl]-1h-indole-2-carboxamide Chemical compound C[C@H]1CCCC[C@H]1NC(=O)C1=CC2=CC=C(C#N)C=C2N1 WVMIUZBFRMIPHI-SMDDNHRTSA-N 0.000 claims description 4
- OUUAPXVQKFXKRS-GXTWGEPZSA-N 6-methyl-n-[(1r,2s)-2-methylcyclohexyl]-1h-indole-2-carboxamide Chemical compound C[C@H]1CCCC[C@H]1NC(=O)C1=CC2=CC=C(C)C=C2N1 OUUAPXVQKFXKRS-GXTWGEPZSA-N 0.000 claims description 4
- LVPQDFMRAJPWDM-UHFFFAOYSA-N 7-chloro-n-(4-methylcyclohexyl)-1h-indole-2-carboxamide Chemical compound C1CC(C)CCC1NC(=O)C1=CC2=CC=CC(Cl)=C2N1 LVPQDFMRAJPWDM-UHFFFAOYSA-N 0.000 claims description 4
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 claims description 4
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 claims description 4
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 claims description 4
- VRDIULHPQTYCLN-UHFFFAOYSA-N Prothionamide Chemical compound CCCC1=CC(C(N)=S)=CC=N1 VRDIULHPQTYCLN-UHFFFAOYSA-N 0.000 claims description 4
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 claims description 4
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 claims description 4
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims description 4
- 229960003022 amoxicillin Drugs 0.000 claims description 4
- 229940121383 antituberculosis agent Drugs 0.000 claims description 4
- MESJKKLEOVJXNZ-HOMQSWHASA-N chembl3086124 Chemical compound C1C[C@@H](C)CC[C@@H]1NC(=O)C1=CC2=C(F)C=C(F)C=C2N1 MESJKKLEOVJXNZ-HOMQSWHASA-N 0.000 claims description 4
- 229940090805 clavulanate Drugs 0.000 claims description 4
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 claims description 4
- WDQPAMHFFCXSNU-BGABXYSRSA-N clofazimine Chemical compound C12=CC=CC=C2N=C2C=C(NC=3C=CC(Cl)=CC=3)C(=N/C(C)C)/C=C2N1C1=CC=C(Cl)C=C1 WDQPAMHFFCXSNU-BGABXYSRSA-N 0.000 claims description 4
- 229960004287 clofazimine Drugs 0.000 claims description 4
- 229960003077 cycloserine Drugs 0.000 claims description 4
- 229960002182 imipenem Drugs 0.000 claims description 4
- 229960003376 levofloxacin Drugs 0.000 claims description 4
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 claims description 4
- 229960003907 linezolid Drugs 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 4
- KLXIQTNTIXYSJA-UHFFFAOYSA-N n-(cyclohexylmethyl)-4,6-dimethyl-1h-indole-2-carboxamide Chemical compound N1C2=CC(C)=CC(C)=C2C=C1C(=O)NCC1CCCCC1 KLXIQTNTIXYSJA-UHFFFAOYSA-N 0.000 claims description 4
- FIMWLESENRVCER-IVMMDQJWSA-N n-[(1r,2s,3r)-2,3-dimethylcyclohexyl]-4,6-dimethyl-1h-indole-2-carboxamide Chemical compound C[C@H]1[C@H](C)CCC[C@H]1NC(=O)C1=CC2=C(C)C=C(C)C=C2N1 FIMWLESENRVCER-IVMMDQJWSA-N 0.000 claims description 4
- FIMWLESENRVCER-XPKDYRNWSA-N n-[(1s,2r,3r)-2,3-dimethylcyclohexyl]-4,6-dimethyl-1h-indole-2-carboxamide Chemical compound C[C@@H]1[C@H](C)CCC[C@@H]1NC(=O)C1=CC2=C(C)C=C(C)C=C2N1 FIMWLESENRVCER-XPKDYRNWSA-N 0.000 claims description 4
- FIMWLESENRVCER-BJJXKVORSA-N n-[(1s,2r,3s)-2,3-dimethylcyclohexyl]-4,6-dimethyl-1h-indole-2-carboxamide Chemical compound C[C@@H]1[C@@H](C)CCC[C@@H]1NC(=O)C1=CC2=C(C)C=C(C)C=C2N1 FIMWLESENRVCER-BJJXKVORSA-N 0.000 claims description 4
- ANRDRZQBFPDAJD-UHFFFAOYSA-N n-cycloheptyl-4,6-dimethyl-1h-indole-2-carboxamide Chemical compound N1C2=CC(C)=CC(C)=C2C=C1C(=O)NC1CCCCCC1 ANRDRZQBFPDAJD-UHFFFAOYSA-N 0.000 claims description 4
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims description 4
- 229960000918 protionamide Drugs 0.000 claims description 4
- 229960005322 streptomycin Drugs 0.000 claims description 4
- 229960003231 thioacetazone Drugs 0.000 claims description 4
- SRVJKTDHMYAMHA-WUXMJOGZSA-N thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 claims description 4
- 229960002784 thioridazine Drugs 0.000 claims description 4
- 239000000814 tuberculostatic agent Substances 0.000 claims description 4
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 claims description 3
- USFUDALBHSUWCW-UHFFFAOYSA-N 4-bromo-n-cycloheptyl-6-(trifluoromethyl)-1h-indole-2-carboxamide Chemical compound N1C2=CC(C(F)(F)F)=CC(Br)=C2C=C1C(=O)NC1CCCCCC1 USFUDALBHSUWCW-UHFFFAOYSA-N 0.000 claims description 3
- NYMJRFRRVIFTRU-UHFFFAOYSA-N 4-chloro-n-(4-methylcyclohexyl)-1h-indole-2-carboxamide Chemical compound C1CC(C)CCC1NC(=O)C1=CC2=C(Cl)C=CC=C2N1 NYMJRFRRVIFTRU-UHFFFAOYSA-N 0.000 claims description 3
- ZDNREMVWQAZTFX-SWLSCSKDSA-N 4-cyano-6-methyl-n-[(1r,2s)-2-methylcyclohexyl]-1h-indole-2-carboxamide Chemical compound C[C@H]1CCCC[C@H]1NC(=O)C1=CC2=C(C#N)C=C(C)C=C2N1 ZDNREMVWQAZTFX-SWLSCSKDSA-N 0.000 claims description 3
- HGJLZOCQPVDNDZ-WKILWMFISA-N C(C)(C)[C@@H]1CC[C@H](CC1)NC(=O)C=1NC2=CC(=CC(=C2C1)C)C Chemical compound C(C)(C)[C@@H]1CC[C@H](CC1)NC(=O)C=1NC2=CC(=CC(=C2C1)C)C HGJLZOCQPVDNDZ-WKILWMFISA-N 0.000 claims description 3
- 229960004909 aminosalicylic acid Drugs 0.000 claims description 3
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims description 3
- 229960002626 clarithromycin Drugs 0.000 claims description 3
- FIMWLESENRVCER-DUVNUKRYSA-N n-[(1r,2s,3s)-2,3-dimethylcyclohexyl]-4,6-dimethyl-1h-indole-2-carboxamide Chemical compound C[C@H]1[C@@H](C)CCC[C@H]1NC(=O)C1=CC2=C(C)C=C(C)C=C2N1 FIMWLESENRVCER-DUVNUKRYSA-N 0.000 claims description 3
- HGJLZOCQPVDNDZ-UHFFFAOYSA-N 4,6-dimethyl-n-(4-propan-2-ylcyclohexyl)-1h-indole-2-carboxamide Chemical compound C1CC(C(C)C)CCC1NC(=O)C1=CC2=C(C)C=C(C)C=C2N1 HGJLZOCQPVDNDZ-UHFFFAOYSA-N 0.000 claims description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Chemical group C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 2
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 claims 2
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 claims 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 83
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 69
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 59
- 239000000203 mixture Substances 0.000 description 55
- 238000004128 high performance liquid chromatography Methods 0.000 description 53
- 238000005160 1H NMR spectroscopy Methods 0.000 description 47
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 36
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 36
- 239000007787 solid Substances 0.000 description 32
- 238000002360 preparation method Methods 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 30
- 238000000034 method Methods 0.000 description 29
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 25
- 239000000243 solution Substances 0.000 description 24
- 239000011541 reaction mixture Substances 0.000 description 21
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 20
- 238000005481 NMR spectroscopy Methods 0.000 description 19
- 229910052805 deuterium Inorganic materials 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 17
- 239000000543 intermediate Substances 0.000 description 17
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 16
- 230000002829 reductive effect Effects 0.000 description 15
- 239000002904 solvent Substances 0.000 description 14
- HCUARRIEZVDMPT-UHFFFAOYSA-N Indole-2-carboxylic acid Chemical class C1=CC=C2NC(C(=O)O)=CC2=C1 HCUARRIEZVDMPT-UHFFFAOYSA-N 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
- 239000012267 brine Substances 0.000 description 12
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 12
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 11
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 11
- 150000002475 indoles Chemical class 0.000 description 11
- 239000007858 starting material Substances 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- 150000001412 amines Chemical class 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 238000010348 incorporation Methods 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 229940124597 therapeutic agent Drugs 0.000 description 10
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 9
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 150000003857 carboxamides Chemical class 0.000 description 9
- 239000012044 organic layer Substances 0.000 description 9
- 229910052938 sodium sulfate Inorganic materials 0.000 description 9
- 235000011152 sodium sulphate Nutrition 0.000 description 9
- NKNGAORFGPSYJG-UHFFFAOYSA-N 4,6-dichloro-n-(4,4-dimethylcyclohexyl)-1h-indole-2-carboxamide Chemical compound C1CC(C)(C)CCC1NC(=O)C1=CC2=C(Cl)C=C(Cl)C=C2N1 NKNGAORFGPSYJG-UHFFFAOYSA-N 0.000 description 8
- UWVBWQMLIKUPJX-UHFFFAOYSA-N 4,6-dichloro-n-[4-(fluoromethyl)cyclohexyl]-1h-indole-2-carboxamide Chemical compound C1CC(CF)CCC1NC(=O)C1=CC2=C(Cl)C=C(Cl)C=C2N1 UWVBWQMLIKUPJX-UHFFFAOYSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 8
- 239000007832 Na2SO4 Substances 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 238000004440 column chromatography Methods 0.000 description 8
- 239000013078 crystal Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 7
- 201000009671 multidrug-resistant tuberculosis Diseases 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000012298 atmosphere Substances 0.000 description 6
- 239000003480 eluent Substances 0.000 description 6
- 150000002429 hydrazines Chemical class 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- DHXISZKSSIWRLH-UHFFFAOYSA-N 4,6-dichloro-1h-indole-2-carboxylic acid Chemical compound C1=C(Cl)C=C2NC(C(=O)O)=CC2=C1Cl DHXISZKSSIWRLH-UHFFFAOYSA-N 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 229940072185 drug for treatment of tuberculosis Drugs 0.000 description 5
- 208000036984 extensively drug-resistant tuberculosis Diseases 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine group Chemical group N1=CCC2=CC=CC=C12 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 5
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 5
- 230000010534 mechanism of action Effects 0.000 description 5
- 239000012453 solvate Substances 0.000 description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 5
- FEUISMYEFPANSS-NKWVEPMBSA-N (1r,2s)-2-methylcyclohexan-1-amine Chemical compound C[C@H]1CCCC[C@H]1N FEUISMYEFPANSS-NKWVEPMBSA-N 0.000 description 4
- SXPXXGMXAGPSQO-UHFFFAOYSA-N 4,6-dichloro-n-(4,4-difluorocyclohexyl)-1h-indole-2-carboxamide Chemical compound C1CC(F)(F)CCC1NC(=O)C1=CC2=C(Cl)C=C(Cl)C=C2N1 SXPXXGMXAGPSQO-UHFFFAOYSA-N 0.000 description 4
- ZMEXZWHYAFXSLS-UHFFFAOYSA-N 4,6-dichloro-n-(4-methylcyclohexyl)-1h-indole-2-carboxamide Chemical compound C1CC(C)CCC1NC(=O)C1=CC2=C(Cl)C=C(Cl)C=C2N1 ZMEXZWHYAFXSLS-UHFFFAOYSA-N 0.000 description 4
- MESJKKLEOVJXNZ-UHFFFAOYSA-N 4,6-difluoro-n-(4-methylcyclohexyl)-1h-indole-2-carboxamide Chemical compound C1CC(C)CCC1NC(=O)C1=CC2=C(F)C=C(F)C=C2N1 MESJKKLEOVJXNZ-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 4
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- JQXXHWHPUNPDRT-BQVAUQFYSA-N chembl1523493 Chemical compound O([C@](C1=O)(C)O\C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2C=NN1CCN(C)CC1 JQXXHWHPUNPDRT-BQVAUQFYSA-N 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 239000011737 fluorine Substances 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000000155 isotopic effect Effects 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 230000002269 spontaneous effect Effects 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- YKJQPGPTKYUTHU-UHFFFAOYSA-N (4,4-dimethylcyclohexyl)azanium;chloride Chemical compound Cl.CC1(C)CCC(N)CC1 YKJQPGPTKYUTHU-UHFFFAOYSA-N 0.000 description 3
- UBIBYOPVQZPBPZ-JVWICGRDSA-N 2-methyl-n-[(1r)-1-phenylethyl]cyclohexan-1-amine Chemical compound N([C@H](C)C=1C=CC=CC=1)C1CCCCC1C UBIBYOPVQZPBPZ-JVWICGRDSA-N 0.000 description 3
- UQRLKWGPEVNVHT-UHFFFAOYSA-N 3,5-dichloroaniline Chemical compound NC1=CC(Cl)=CC(Cl)=C1 UQRLKWGPEVNVHT-UHFFFAOYSA-N 0.000 description 3
- XAZGAMBLSWQUSS-UHFFFAOYSA-N 4,6-dichloro-n-[4-(trifluoromethyl)cyclohexyl]-1h-indole-2-carboxamide Chemical compound C1CC(C(F)(F)F)CCC1NC(=O)C1=CC2=C(Cl)C=C(Cl)C=C2N1 XAZGAMBLSWQUSS-UHFFFAOYSA-N 0.000 description 3
- XCETYXTZPDOMHK-UHFFFAOYSA-N 4,6-dimethyl-n-(2-methylcyclohexyl)-1h-indole-2-carboxamide Chemical compound CC1CCCCC1NC(=O)C1=CC2=C(C)C=C(C)C=C2N1 XCETYXTZPDOMHK-UHFFFAOYSA-N 0.000 description 3
- KAXUOBJYDHIAML-SMDDNHRTSA-N 4,6-dimethyl-n-[(1r,2s)-2-methylcyclopentyl]-1h-indole-2-carboxamide Chemical compound C[C@H]1CCC[C@H]1NC(=O)C1=CC2=C(C)C=C(C)C=C2N1 KAXUOBJYDHIAML-SMDDNHRTSA-N 0.000 description 3
- BFIROIIOMSHZAA-SMDDNHRTSA-N 4-bromo-6-methyl-n-[(1r,2s)-2-methylcyclohexyl]-1h-indole-2-carboxamide Chemical compound C[C@H]1CCCC[C@H]1NC(=O)C1=CC2=C(Br)C=C(C)C=C2N1 BFIROIIOMSHZAA-SMDDNHRTSA-N 0.000 description 3
- HEESFEOUXIPQIB-UHFFFAOYSA-N 6,7-dichloro-n-(4-methylcyclohexyl)-1h-indole-2-carboxamide Chemical compound C1CC(C)CCC1NC(=O)C1=CC2=CC=C(Cl)C(Cl)=C2N1 HEESFEOUXIPQIB-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- QUFWGZNPFSXWOS-ZGTCLIOFSA-N CC1C(CCCC1)=N[C@H](C)C1=CC=CC=C1 Chemical compound CC1C(CCCC1)=N[C@H](C)C1=CC=CC=C1 QUFWGZNPFSXWOS-ZGTCLIOFSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 101100023564 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) mmpL3 gene Proteins 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 150000001448 anilines Chemical class 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 210000002421 cell wall Anatomy 0.000 description 3
- ZMEXZWHYAFXSLS-JGZJWPJOSA-N chembl3086125 Chemical compound C1C[C@@H](C)CC[C@H]1NC(=O)C1=CC2=C(Cl)C=C(Cl)C=C2N1 ZMEXZWHYAFXSLS-JGZJWPJOSA-N 0.000 description 3
- ZMEXZWHYAFXSLS-HOMQSWHASA-N chembl3086126 Chemical compound C1C[C@@H](C)CC[C@@H]1NC(=O)C1=CC2=C(Cl)C=C(Cl)C=C2N1 ZMEXZWHYAFXSLS-HOMQSWHASA-N 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 239000008121 dextrose Substances 0.000 description 3
- 239000012954 diazonium Substances 0.000 description 3
- 150000001989 diazonium salts Chemical class 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- YLAHLUPONQVSOT-UHFFFAOYSA-N ethyl 4,6-dichloro-1h-indole-2-carboxylate Chemical compound C1=C(Cl)C=C2NC(C(=O)OCC)=CC2=C1Cl YLAHLUPONQVSOT-UHFFFAOYSA-N 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical group 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 229920000137 polyphosphoric acid Polymers 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 238000002953 preparative HPLC Methods 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 235000017550 sodium carbonate Nutrition 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- GTUIRORNXIOHQR-VIFPVBQESA-N 2-[(3s)-3-methyl-1,4-dioxa-8-azaspiro[4.5]decan-8-yl]-8-nitro-6-(trifluoromethyl)-1,3-benzothiazin-4-one Chemical compound O1[C@@H](C)COC11CCN(C=2SC3=C([N+]([O-])=O)C=C(C=C3C(=O)N=2)C(F)(F)F)CC1 GTUIRORNXIOHQR-VIFPVBQESA-N 0.000 description 2
- BXCUMAUHMPSRPZ-UHFFFAOYSA-N 3,4,5-trimethylaniline Chemical compound CC1=CC(N)=CC(C)=C1C BXCUMAUHMPSRPZ-UHFFFAOYSA-N 0.000 description 2
- KQOIBXZRCYFZSO-UHFFFAOYSA-N 3,5-difluoroaniline Chemical compound NC1=CC(F)=CC(F)=C1 KQOIBXZRCYFZSO-UHFFFAOYSA-N 0.000 description 2
- VIUDTWATMPPKEL-UHFFFAOYSA-N 3-(trifluoromethyl)aniline Chemical compound NC1=CC=CC(C(F)(F)F)=C1 VIUDTWATMPPKEL-UHFFFAOYSA-N 0.000 description 2
- JJYPMNFTHPTTDI-UHFFFAOYSA-N 3-methylaniline Chemical compound CC1=CC=CC(N)=C1 JJYPMNFTHPTTDI-UHFFFAOYSA-N 0.000 description 2
- CAUXQOLTFGCRKD-UHFFFAOYSA-N 4,4-dimethylcyclohexan-1-amine Chemical compound CC1(C)CCC(N)CC1 CAUXQOLTFGCRKD-UHFFFAOYSA-N 0.000 description 2
- GCLXGYUHFKHLEH-UHFFFAOYSA-N 4,6-dichloro-n-(1-ethynylcyclohexyl)-1h-indole-2-carboxamide Chemical compound N1C2=CC(Cl)=CC(Cl)=C2C=C1C(=O)NC1(C#C)CCCCC1 GCLXGYUHFKHLEH-UHFFFAOYSA-N 0.000 description 2
- SOUVDADHAWNAAR-UHFFFAOYSA-N 4,6-dichloro-n-(2-ethynylcyclohexyl)-1h-indole-2-carboxamide Chemical compound N1C2=CC(Cl)=CC(Cl)=C2C=C1C(=O)NC1CCCCC1C#C SOUVDADHAWNAAR-UHFFFAOYSA-N 0.000 description 2
- JKXCORRVLFGYSE-TVQRCGJNSA-N 4,6-dichloro-n-[(1r,2s)-2-methylcyclohexyl]-1h-indole-2-carboxamide Chemical compound C[C@H]1CCCC[C@H]1NC(=O)C1=CC2=C(Cl)C=C(Cl)C=C2N1 JKXCORRVLFGYSE-TVQRCGJNSA-N 0.000 description 2
- CCNGUBMPKAMAPM-UHFFFAOYSA-N 4,6-dicyano-n-(4-methylcyclohexyl)-1h-indole-2-carboxamide Chemical compound C1CC(C)CCC1NC(=O)C1=CC2=C(C#N)C=C(C#N)C=C2N1 CCNGUBMPKAMAPM-UHFFFAOYSA-N 0.000 description 2
- OCHGGXDZJGAUEU-UHFFFAOYSA-N 4,6-difluoro-1h-indole-2-carboxylic acid Chemical compound C1=C(F)C=C2NC(C(=O)O)=CC2=C1F OCHGGXDZJGAUEU-UHFFFAOYSA-N 0.000 description 2
- PLCNMKNGMALFCQ-TVQRCGJNSA-N 4,6-difluoro-n-[(1r,2s)-2-methylcyclohexyl]-1h-indole-2-carboxamide Chemical compound C[C@H]1CCCC[C@H]1NC(=O)C1=CC2=C(F)C=C(F)C=C2N1 PLCNMKNGMALFCQ-TVQRCGJNSA-N 0.000 description 2
- XCETYXTZPDOMHK-SWLSCSKDSA-N 4,6-dimethyl-n-[(1r,2s)-2-methylcyclohexyl]-1h-indole-2-carboxamide Chemical compound C[C@H]1CCCC[C@H]1NC(=O)C1=CC2=C(C)C=C(C)C=C2N1 XCETYXTZPDOMHK-SWLSCSKDSA-N 0.000 description 2
- RRSJIPBQQRCMSH-UHFFFAOYSA-N 4,7-dichloro-n-(4-methylcyclohexyl)-1h-indole-2-carboxamide Chemical compound C1CC(C)CCC1NC(=O)C1=CC2=C(Cl)C=CC(Cl)=C2N1 RRSJIPBQQRCMSH-UHFFFAOYSA-N 0.000 description 2
- KSMVBYPXNKCPAJ-UHFFFAOYSA-N 4-Methylcyclohexylamine Chemical compound CC1CCC(N)CC1 KSMVBYPXNKCPAJ-UHFFFAOYSA-N 0.000 description 2
- AUZXOWJDIYDGJU-UHFFFAOYSA-N 4-cyano-1h-indole-2-carboxylic acid Chemical compound C1=CC=C2NC(C(=O)O)=CC2=C1C#N AUZXOWJDIYDGJU-UHFFFAOYSA-N 0.000 description 2
- SRMXTBWDYROABJ-UHFFFAOYSA-N 4-cyano-6-isocyano-n-(4-methylcyclohexyl)-1h-indole-2-carboxamide Chemical compound C1CC(C)CCC1NC(=O)C1=CC2=C(C#N)C=C([N+]#[C-])C=C2N1 SRMXTBWDYROABJ-UHFFFAOYSA-N 0.000 description 2
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-dimethylaminophenol Chemical compound CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-dimethylaminopyridine Substances CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- ALWBHLOYBDHTAA-UHFFFAOYSA-N 4-fluoro-n-(4-methylcyclohexyl)-1h-indole-2-carboxamide Chemical compound C1CC(C)CCC1NC(=O)C1=CC2=C(F)C=CC=C2N1 ALWBHLOYBDHTAA-UHFFFAOYSA-N 0.000 description 2
- NHOKKNZGFARWHQ-GXFFZTMASA-N 4-fluoro-n-[(1r,2s)-2-methylcyclohexyl]-1h-indole-2-carboxamide Chemical compound C[C@H]1CCCC[C@H]1NC(=O)C1=CC2=C(F)C=CC=C2N1 NHOKKNZGFARWHQ-GXFFZTMASA-N 0.000 description 2
- MFRKYEJMLQUSJX-UHFFFAOYSA-N 4-propan-2-ylcyclohexan-1-amine Chemical compound CC(C)C1CCC(N)CC1 MFRKYEJMLQUSJX-UHFFFAOYSA-N 0.000 description 2
- YKTBVHWIRASIOS-UHFFFAOYSA-N 6-cyano-n-(4,4-difluorocyclohexyl)-1h-indole-2-carboxamide Chemical compound C1CC(F)(F)CCC1NC(=O)C1=CC2=CC=C(C#N)C=C2N1 YKTBVHWIRASIOS-UHFFFAOYSA-N 0.000 description 2
- AVQHWRGHYBKBBV-UHFFFAOYSA-N 6-fluoro-n-(4-methylcyclohexyl)-1h-indole-2-carboxamide Chemical compound C1CC(C)CCC1NC(=O)C1=CC2=CC=C(F)C=C2N1 AVQHWRGHYBKBBV-UHFFFAOYSA-N 0.000 description 2
- PBYQZRDWUJSMFN-GXFFZTMASA-N 6-fluoro-n-[(1r,2s)-2-methylcyclohexyl]-1h-indole-2-carboxamide Chemical compound C[C@H]1CCCC[C@H]1NC(=O)C1=CC2=CC=C(F)C=C2N1 PBYQZRDWUJSMFN-GXFFZTMASA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- 102100027211 Albumin Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 108010019625 Atazanavir Sulfate Proteins 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- CCNGUBMPKAMAPM-YEORSEQZSA-N C(#N)C1=C2C=C(NC2=CC(=C1)C#N)C(=O)N[C@@H]1CC[C@H](CC1)C Chemical compound C(#N)C1=C2C=C(NC2=CC(=C1)C#N)C(=O)N[C@@H]1CC[C@H](CC1)C CCNGUBMPKAMAPM-YEORSEQZSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 108010032976 Enfuvirtide Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102000003939 Membrane transport proteins Human genes 0.000 description 2
- 108090000301 Membrane transport proteins Proteins 0.000 description 2
- 241000186359 Mycobacterium Species 0.000 description 2
- 241000186362 Mycobacterium leprae Species 0.000 description 2
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- AXRYRYVKAWYZBR-GASGPIRDSA-N atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 150000003935 benzaldehydes Chemical class 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- VEZUQRBDRNJBJY-UHFFFAOYSA-N cyclohexanone oxime Chemical compound ON=C1CCCCC1 VEZUQRBDRNJBJY-UHFFFAOYSA-N 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- CJBJHOAVZSMMDJ-HEXNFIEUSA-N darunavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C1=CC=CC=C1 CJBJHOAVZSMMDJ-HEXNFIEUSA-N 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 150000001975 deuterium Chemical group 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 2
- PEASPLKKXBYDKL-FXEVSJAOSA-N enfuvirtide Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C1=CN=CN1 PEASPLKKXBYDKL-FXEVSJAOSA-N 0.000 description 2
- PYGWGZALEOIKDF-UHFFFAOYSA-N etravirine Chemical compound CC1=CC(C#N)=CC(C)=C1OC1=NC(NC=2C=CC(=CC=2)C#N)=NC(N)=C1Br PYGWGZALEOIKDF-UHFFFAOYSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000012847 fine chemical Substances 0.000 description 2
- 235000021472 generally recognized as safe Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000003966 growth inhibitor Substances 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 238000013537 high throughput screening Methods 0.000 description 2
- 150000002431 hydrogen Chemical group 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- GSOSVVULSKVSLQ-JJVRHELESA-N imipenem hydrate Chemical compound O.C1C(SCCNC=N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 GSOSVVULSKVSLQ-JJVRHELESA-N 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- GSNHKUDZZFZSJB-QYOOZWMWSA-N maraviroc Chemical compound CC(C)C1=NN=C(C)N1[C@@H]1C[C@H](N2CC[C@H](NC(=O)C3CCC(F)(F)CC3)C=3C=CC=CC=3)CC[C@H]2C1 GSNHKUDZZFZSJB-QYOOZWMWSA-N 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- IJGLUXGAALWDOQ-UHFFFAOYSA-N n-(4,4-dimethylcyclohexylidene)hydroxylamine Chemical compound CC1(C)CCC(=NO)CC1 IJGLUXGAALWDOQ-UHFFFAOYSA-N 0.000 description 2
- XVOSAUUTVGEQGZ-TVQRCGJNSA-N n-[(1r,2s)-2-methylcyclohexyl]-4,6-bis(trifluoromethyl)-1h-indole-2-carboxamide Chemical compound C[C@H]1CCCC[C@H]1NC(=O)C1=CC2=C(C(F)(F)F)C=C(C(F)(F)F)C=C2N1 XVOSAUUTVGEQGZ-TVQRCGJNSA-N 0.000 description 2
- XYZABHKYCIZTPI-UHFFFAOYSA-N n-cyclohexyl-4,6-difluoro-1h-indole-2-carboxamide Chemical compound N1C2=CC(F)=CC(F)=C2C=C1C(=O)NC1CCCCC1 XYZABHKYCIZTPI-UHFFFAOYSA-N 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 238000005897 peptide coupling reaction Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- CZFFBEXEKNGXKS-UHFFFAOYSA-N raltegravir Chemical compound O1C(C)=NN=C1C(=O)NC(C)(C)C1=NC(C(=O)NCC=2C=CC(F)=CC=2)=C(O)C(=O)N1C CZFFBEXEKNGXKS-UHFFFAOYSA-N 0.000 description 2
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 235000011150 stannous chloride Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 125000000647 trehalose group Chemical group 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 description 1
- RQEUFEKYXDPUSK-SSDOTTSWSA-N (1R)-1-phenylethanamine Chemical compound C[C@@H](N)C1=CC=CC=C1 RQEUFEKYXDPUSK-SSDOTTSWSA-N 0.000 description 1
- KNSSNWJVWLWDSO-ARIDFIBWSA-N (1R,2S,3R)-2,3-dimethylcyclohexan-1-amine hydrochloride Chemical compound Cl.C[C@@H]1CCC[C@@H](N)[C@H]1C KNSSNWJVWLWDSO-ARIDFIBWSA-N 0.000 description 1
- KNSSNWJVWLWDSO-CGJXVAEWSA-N (1R,2S,3S)-2,3-dimethylcyclohexan-1-amine hydrochloride Chemical compound Cl.C[C@@H]1[C@@H](CCC[C@@H]1C)N KNSSNWJVWLWDSO-CGJXVAEWSA-N 0.000 description 1
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- FEUISMYEFPANSS-RNFRBKRXSA-N (1r,2r)-2-methylcyclohexan-1-amine Chemical compound C[C@@H]1CCCC[C@H]1N FEUISMYEFPANSS-RNFRBKRXSA-N 0.000 description 1
- TYDMZADCGUWTCH-NTSWFWBYSA-N (1r,2s)-2-methylcyclopentan-1-amine Chemical compound C[C@H]1CCC[C@H]1N TYDMZADCGUWTCH-NTSWFWBYSA-N 0.000 description 1
- KHKJUJGNSSJMED-RITPCOANSA-N (1s,2r)-2-(trifluoromethyl)cyclohexan-1-amine Chemical compound N[C@H]1CCCC[C@H]1C(F)(F)F KHKJUJGNSSJMED-RITPCOANSA-N 0.000 description 1
- LKWOOKWVBNSLGN-RNJXMRFFSA-N (1s,2r,3s)-2,3-dimethylcyclohexan-1-amine Chemical compound C[C@H]1CCC[C@H](N)[C@@H]1C LKWOOKWVBNSLGN-RNJXMRFFSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- GIRKJSRZELQHDX-UHFFFAOYSA-N (4-methylcyclohexyl)azanium;chloride Chemical compound Cl.CC1CCC(N)CC1 GIRKJSRZELQHDX-UHFFFAOYSA-N 0.000 description 1
- ZLHZLMOSPGACSZ-NSHDSACASA-N (6s)-2-nitro-6-[[4-(trifluoromethoxy)phenyl]methoxy]-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazine Chemical compound O([C@H]1CN2C=C(N=C2OC1)[N+](=O)[O-])CC1=CC=C(OC(F)(F)F)C=C1 ZLHZLMOSPGACSZ-NSHDSACASA-N 0.000 description 1
- ZXSGSFMORAILEY-HNNXBMFYSA-N (6s)-2-nitro-6-[[6-[4-(trifluoromethoxy)phenyl]pyridin-3-yl]methoxy]-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazine Chemical compound O([C@H]1CN2C=C(N=C2OC1)[N+](=O)[O-])CC(C=N1)=CC=C1C1=CC=C(OC(F)(F)F)C=C1 ZXSGSFMORAILEY-HNNXBMFYSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- XGNXYCFREOZBOL-UHFFFAOYSA-N 1,3-benzodioxol-5-amine Chemical compound NC1=CC=C2OCOC2=C1 XGNXYCFREOZBOL-UHFFFAOYSA-N 0.000 description 1
- QUIJNHUBAXPXFS-UHFFFAOYSA-N 1-(6-bromo-2-methoxyquinolin-3-yl)-4-(dimethylamino)-2-naphthalen-1-yl-1-phenylbutan-2-ol Chemical compound COC1=NC2=CC=C(Br)C=C2C=C1C(C(O)(CCN(C)C)C=1C2=CC=CC=C2C=CC=1)C1=CC=CC=C1 QUIJNHUBAXPXFS-UHFFFAOYSA-N 0.000 description 1
- SKOKCVXJNYWBHQ-UHFFFAOYSA-N 1-anilinoindole-2-carboxamide Chemical compound C1(=CC=CC=C1)NN1C(=CC2=CC=CC=C12)C(=O)N SKOKCVXJNYWBHQ-UHFFFAOYSA-N 0.000 description 1
- QHDRTYODAWKNCU-UHFFFAOYSA-N 1-cyanoindole-2-carboxylic acid Chemical compound C1=CC=C2N(C#N)C(C(=O)O)=CC2=C1 QHDRTYODAWKNCU-UHFFFAOYSA-N 0.000 description 1
- GDKOYYDQISQOMH-UHFFFAOYSA-N 1-ethynylcyclohexan-1-amine Chemical compound C#CC1(N)CCCCC1 GDKOYYDQISQOMH-UHFFFAOYSA-N 0.000 description 1
- LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- MOTBXEPLFOLWHZ-UHFFFAOYSA-N 2,3,5-trichloroaniline Chemical compound NC1=CC(Cl)=CC(Cl)=C1Cl MOTBXEPLFOLWHZ-UHFFFAOYSA-N 0.000 description 1
- BRPSAOUFIJSKOT-UHFFFAOYSA-N 2,3-dichloroaniline Chemical compound NC1=CC=CC(Cl)=C1Cl BRPSAOUFIJSKOT-UHFFFAOYSA-N 0.000 description 1
- YCCQGFYAVUTQFK-UHFFFAOYSA-N 2,3-difluoroaniline Chemical compound NC1=CC=CC(F)=C1F YCCQGFYAVUTQFK-UHFFFAOYSA-N 0.000 description 1
- AVYGCQXNNJPXSS-UHFFFAOYSA-N 2,5-dichloroaniline Chemical compound NC1=CC(Cl)=CC=C1Cl AVYGCQXNNJPXSS-UHFFFAOYSA-N 0.000 description 1
- YNOOQIUSYGWMSS-UHFFFAOYSA-N 2,5-difluoroaniline Chemical compound NC1=CC(F)=CC=C1F YNOOQIUSYGWMSS-UHFFFAOYSA-N 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- KHKJUJGNSSJMED-UHFFFAOYSA-N 2-(trifluoromethyl)cyclohexan-1-amine Chemical compound NC1CCCCC1C(F)(F)F KHKJUJGNSSJMED-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
- WXHLLJAMBQLULT-UHFFFAOYSA-N 2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-n-(2-methyl-6-sulfanylphenyl)-1,3-thiazole-5-carboxamide;hydrate Chemical compound O.C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1S WXHLLJAMBQLULT-UHFFFAOYSA-N 0.000 description 1
- AOPBDRUWRLBSDB-UHFFFAOYSA-N 2-bromoaniline Chemical compound NC1=CC=CC=C1Br AOPBDRUWRLBSDB-UHFFFAOYSA-N 0.000 description 1
- AKCRQHGQIJBRMN-UHFFFAOYSA-N 2-chloroaniline Chemical compound NC1=CC=CC=C1Cl AKCRQHGQIJBRMN-UHFFFAOYSA-N 0.000 description 1
- FTZQXOJYPFINKJ-UHFFFAOYSA-N 2-fluoroaniline Chemical compound NC1=CC=CC=C1F FTZQXOJYPFINKJ-UHFFFAOYSA-N 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- FEUISMYEFPANSS-UHFFFAOYSA-N 2-methylcyclohexan-1-amine Chemical compound CC1CCCCC1N FEUISMYEFPANSS-UHFFFAOYSA-N 0.000 description 1
- LFSAPCRASZRSKS-UHFFFAOYSA-N 2-methylcyclohexan-1-one Chemical compound CC1CCCCC1=O LFSAPCRASZRSKS-UHFFFAOYSA-N 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- TYEYBOSBBBHJIV-UHFFFAOYSA-N 2-oxobutanoic acid Chemical compound CCC(=O)C(O)=O TYEYBOSBBBHJIV-UHFFFAOYSA-N 0.000 description 1
- IUUHHWALHWRYPY-UHFFFAOYSA-N 2-propan-2-ylcyclohexan-1-amine Chemical compound CC(C)C1CCCCC1N IUUHHWALHWRYPY-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- XEFRNCLPPFDWAC-UHFFFAOYSA-N 3,4,5-trimethoxyaniline Chemical compound COC1=CC(N)=CC(OC)=C1OC XEFRNCLPPFDWAC-UHFFFAOYSA-N 0.000 description 1
- LGDHZCLREKIGKJ-UHFFFAOYSA-N 3,4-dimethoxyaniline Chemical compound COC1=CC=C(N)C=C1OC LGDHZCLREKIGKJ-UHFFFAOYSA-N 0.000 description 1
- PGHCWYKFUQBGRW-UHFFFAOYSA-N 3,4-dimethylaniline;3,5-dimethylaniline Chemical compound CC1=CC(C)=CC(N)=C1.CC1=CC=C(N)C=C1C PGHCWYKFUQBGRW-UHFFFAOYSA-N 0.000 description 1
- AYWHJTCRGGXKSW-UHFFFAOYSA-N 3,4-dimethylindole-2-carboxylic acid Chemical compound C1=CC(C)=C2C(C)=C(C(O)=O)NC2=C1 AYWHJTCRGGXKSW-UHFFFAOYSA-N 0.000 description 1
- WNRGWPVJGDABME-UHFFFAOYSA-N 3,5-Dimethoxyaniline Chemical compound COC1=CC(N)=CC(OC)=C1 WNRGWPVJGDABME-UHFFFAOYSA-N 0.000 description 1
- CDIDGWDGQGVCIB-UHFFFAOYSA-N 3,5-bis(trifluoromethyl)aniline Chemical compound NC1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 CDIDGWDGQGVCIB-UHFFFAOYSA-N 0.000 description 1
- UNPIGVYJSNRGBR-UHFFFAOYSA-N 3-amino-5-methylbenzonitrile Chemical compound CC1=CC(N)=CC(C#N)=C1 UNPIGVYJSNRGBR-UHFFFAOYSA-N 0.000 description 1
- NJXPYZHXZZCTNI-UHFFFAOYSA-N 3-aminobenzonitrile Chemical compound NC1=CC=CC(C#N)=C1 NJXPYZHXZZCTNI-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- YIZRPAWCIFTHNA-UHFFFAOYSA-N 3-bromo-5-methylaniline Chemical compound CC1=CC(N)=CC(Br)=C1 YIZRPAWCIFTHNA-UHFFFAOYSA-N 0.000 description 1
- DHYHYLGCQVVLOQ-UHFFFAOYSA-N 3-bromoaniline Chemical compound NC1=CC=CC(Br)=C1 DHYHYLGCQVVLOQ-UHFFFAOYSA-N 0.000 description 1
- LPIFAHAICWJMRR-UHFFFAOYSA-N 3-chloro-5-fluoroaniline Chemical compound NC1=CC(F)=CC(Cl)=C1 LPIFAHAICWJMRR-UHFFFAOYSA-N 0.000 description 1
- PNPCRKVUWYDDST-UHFFFAOYSA-N 3-chloroaniline Chemical compound NC1=CC=CC(Cl)=C1 PNPCRKVUWYDDST-UHFFFAOYSA-N 0.000 description 1
- JYDYHSHPBDZRPU-UHFFFAOYSA-N 3-methylcyclohexan-1-amine Chemical compound CC1CCCC(N)C1 JYDYHSHPBDZRPU-UHFFFAOYSA-N 0.000 description 1
- ZJWLMZURLIHVHE-UHFFFAOYSA-N 3-morpholin-4-ylaniline Chemical compound NC1=CC=CC(N2CCOCC2)=C1 ZJWLMZURLIHVHE-UHFFFAOYSA-N 0.000 description 1
- IUYRKPIBACUIQP-UHFFFAOYSA-N 3-n-(2-methylpropyl)benzene-1,3-diamine Chemical compound CC(C)CNC1=CC=CC(N)=C1 IUYRKPIBACUIQP-UHFFFAOYSA-N 0.000 description 1
- PWWYRIBQIWQWMP-UHFFFAOYSA-N 3-n-butan-2-ylbenzene-1,3-diamine Chemical compound CCC(C)NC1=CC=CC(N)=C1 PWWYRIBQIWQWMP-UHFFFAOYSA-N 0.000 description 1
- HSIGVRYBFMXULS-UHFFFAOYSA-N 3-n-butylbenzene-1,3-diamine Chemical compound CCCCNC1=CC=CC(N)=C1 HSIGVRYBFMXULS-UHFFFAOYSA-N 0.000 description 1
- WLAWDMHLJNVGSV-UHFFFAOYSA-N 3-n-ethylbenzene-1,3-diamine Chemical compound CCNC1=CC=CC(N)=C1 WLAWDMHLJNVGSV-UHFFFAOYSA-N 0.000 description 1
- DYNWNNKAUGBOOZ-UHFFFAOYSA-N 3-n-methylbenzene-1,3-diamine Chemical compound CNC1=CC=CC(N)=C1 DYNWNNKAUGBOOZ-UHFFFAOYSA-N 0.000 description 1
- VJTZHXQAZLGBHV-UHFFFAOYSA-N 3-n-phenylbenzene-1,3-diamine Chemical compound NC1=CC=CC(NC=2C=CC=CC=2)=C1 VJTZHXQAZLGBHV-UHFFFAOYSA-N 0.000 description 1
- PLKKXOGVPVZQSZ-UHFFFAOYSA-N 3-n-propan-2-ylbenzene-1,3-diamine Chemical compound CC(C)NC1=CC=CC(N)=C1 PLKKXOGVPVZQSZ-UHFFFAOYSA-N 0.000 description 1
- VXISGCAONOYOFN-UHFFFAOYSA-N 3-n-propylbenzene-1,3-diamine Chemical compound CCCNC1=CC=CC(N)=C1 VXISGCAONOYOFN-UHFFFAOYSA-N 0.000 description 1
- LLGIUNOUQTUAEY-UHFFFAOYSA-N 3-n-tert-butylbenzene-1,3-diamine Chemical compound CC(C)(C)NC1=CC=CC(N)=C1 LLGIUNOUQTUAEY-UHFFFAOYSA-N 0.000 description 1
- XMVRISGEQIGXJB-UHFFFAOYSA-N 3-piperazin-1-ylaniline Chemical compound NC1=CC=CC(N2CCNCC2)=C1 XMVRISGEQIGXJB-UHFFFAOYSA-N 0.000 description 1
- MQOFXVWAFFJFJH-UHFFFAOYSA-N 4,4-difluorocyclohexan-1-amine Chemical compound NC1CCC(F)(F)CC1 MQOFXVWAFFJFJH-UHFFFAOYSA-N 0.000 description 1
- PXQMSTLNSHMSJB-UHFFFAOYSA-N 4,4-dimethylcyclohexan-1-one Chemical compound CC1(C)CCC(=O)CC1 PXQMSTLNSHMSJB-UHFFFAOYSA-N 0.000 description 1
- CMMJGIGVTIJHPK-UHFFFAOYSA-N 4,6-dichloro-n-[4-(hydroxymethyl)cyclohexyl]-1h-indole-2-carboxamide Chemical compound C1CC(CO)CCC1NC(=O)C1=CC2=C(Cl)C=C(Cl)C=C2N1 CMMJGIGVTIJHPK-UHFFFAOYSA-N 0.000 description 1
- POLSKQQIQWLYSN-UHFFFAOYSA-N 4,6-dicyano-1h-indole-2-carboxylic acid Chemical compound C1=C(C#N)C=C2NC(C(=O)O)=CC2=C1C#N POLSKQQIQWLYSN-UHFFFAOYSA-N 0.000 description 1
- DQERMEAKGHXQMM-UHFFFAOYSA-N 4,6-difluoro-n-[4-(trifluoromethyl)cyclohexyl]-1h-indole-2-carboxamide Chemical compound N1C2=CC(F)=CC(F)=C2C=C1C(=O)NC1CCC(C(F)(F)F)CC1 DQERMEAKGHXQMM-UHFFFAOYSA-N 0.000 description 1
- HRHYVQGVACIBPS-UHFFFAOYSA-N 4,6-dimethyl-1h-indole-2-carboxylic acid Chemical compound CC1=CC(C)=C2C=C(C(O)=O)NC2=C1 HRHYVQGVACIBPS-UHFFFAOYSA-N 0.000 description 1
- XCETYXTZPDOMHK-DOMZBBRYSA-N 4,6-dimethyl-n-[(1s,2r)-2-methylcyclohexyl]-1h-indole-2-carboxamide Chemical compound C[C@@H]1CCCC[C@@H]1NC(=O)C1=CC2=C(C)C=C(C)C=C2N1 XCETYXTZPDOMHK-DOMZBBRYSA-N 0.000 description 1
- OHXSJBXQVFRXJB-UHFFFAOYSA-N 4,6-dimethyl-n-[2-(trifluoromethyl)cyclohexyl]-1h-indole-2-carboxamide Chemical compound N1C2=CC(C)=CC(C)=C2C=C1C(=O)NC1CCCCC1C(F)(F)F OHXSJBXQVFRXJB-UHFFFAOYSA-N 0.000 description 1
- LMYQVAQDBJJBEM-UHFFFAOYSA-N 4,7-dichloro-1h-indole-2-carboxylic acid Chemical compound C1=CC(Cl)=C2NC(C(=O)O)=CC2=C1Cl LMYQVAQDBJJBEM-UHFFFAOYSA-N 0.000 description 1
- YCBWLMWEQURJHX-UHFFFAOYSA-N 4-(trifluoromethyl)cyclohexan-1-amine Chemical compound NC1CCC(C(F)(F)F)CC1 YCBWLMWEQURJHX-UHFFFAOYSA-N 0.000 description 1
- LHCOVOKZWQYODM-CPEOKENHSA-N 4-amino-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one;1-[(2r,4s,5s)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1.O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 LHCOVOKZWQYODM-CPEOKENHSA-N 0.000 description 1
- VERWQPYQDXWOGT-LVJNJWHOSA-N 4-amino-5-fluoro-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one;[[(2r)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(propan-2-yloxycarbonyloxymethoxy)phosphoryl]oxymethyl propan-2-yl carbonate;(e)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VERWQPYQDXWOGT-LVJNJWHOSA-N 0.000 description 1
- SXFVRIRMDXONCT-UHFFFAOYSA-N 4-bromo-1h-indole-2-carboxylic acid Chemical compound C1=CC=C2NC(C(=O)O)=CC2=C1Br SXFVRIRMDXONCT-UHFFFAOYSA-N 0.000 description 1
- VXZHQADIRFFCMJ-UHFFFAOYSA-N 4-chloro-1h-indole-2-carboxylic acid Chemical compound C1=CC=C2NC(C(=O)O)=CC2=C1Cl VXZHQADIRFFCMJ-UHFFFAOYSA-N 0.000 description 1
- RDHOUUUIUOTJBC-UHFFFAOYSA-N 4-chloro-6-fluoro-1h-indole-2-carboxylic acid Chemical compound C1=C(F)C=C2NC(C(=O)O)=CC2=C1Cl RDHOUUUIUOTJBC-UHFFFAOYSA-N 0.000 description 1
- KBWWCYDFHITBFO-UHFFFAOYSA-N 4-fluoro-1h-indole-2-carboxylic acid Chemical compound C1=CC=C2NC(C(=O)O)=CC2=C1F KBWWCYDFHITBFO-UHFFFAOYSA-N 0.000 description 1
- QMSCXKCJGFIXDF-UHFFFAOYSA-N 4-methyl-1h-indole-2-carboxylic acid Chemical compound CC1=CC=CC2=C1C=C(C(O)=O)N2 QMSCXKCJGFIXDF-UHFFFAOYSA-N 0.000 description 1
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 1
- UBFORUHJOUPFHX-UHFFFAOYSA-N 5-aminobenzene-1,3-dicarbonitrile Chemical compound NC1=CC(C#N)=CC(C#N)=C1 UBFORUHJOUPFHX-UHFFFAOYSA-N 0.000 description 1
- FUQOTYRCMBZFOL-UHFFFAOYSA-N 5-chloro-1H-indole-2-carboxylic acid Chemical compound ClC1=CC=C2NC(C(=O)O)=CC2=C1 FUQOTYRCMBZFOL-UHFFFAOYSA-N 0.000 description 1
- TUXCSCQQWQOWDU-UHFFFAOYSA-N 6,7-dichloro-1h-indole-2-carboxylic acid Chemical compound C1=C(Cl)C(Cl)=C2NC(C(=O)O)=CC2=C1 TUXCSCQQWQOWDU-UHFFFAOYSA-N 0.000 description 1
- SVBVYRYROZWKNJ-UHFFFAOYSA-N 6-bromo-1h-indole-2-carboxylic acid Chemical compound C1=C(Br)C=C2NC(C(=O)O)=CC2=C1 SVBVYRYROZWKNJ-UHFFFAOYSA-N 0.000 description 1
- BKPSJOSKWKTWAG-UHFFFAOYSA-N 6-chloro-1h-indole-2-carboxylic acid Chemical compound C1=C(Cl)C=C2NC(C(=O)O)=CC2=C1 BKPSJOSKWKTWAG-UHFFFAOYSA-N 0.000 description 1
- WXQBCNRBBDRVJD-UHFFFAOYSA-N 6-chloro-4-fluoro-1h-indole-2-carboxylic acid Chemical compound C1=C(Cl)C=C2NC(C(=O)O)=CC2=C1F WXQBCNRBBDRVJD-UHFFFAOYSA-N 0.000 description 1
- ZRYKZLGQDZSCCL-UHFFFAOYSA-N 6-cyano-n-cyclohexyl-1h-indole-2-carboxamide Chemical compound C=1C2=CC=C(C#N)C=C2NC=1C(=O)NC1CCCCC1 ZRYKZLGQDZSCCL-UHFFFAOYSA-N 0.000 description 1
- LRTIKMXIKAOCDM-UHFFFAOYSA-N 6-fluoro-1h-indole-2-carboxylic acid Chemical compound C1=C(F)C=C2NC(C(=O)O)=CC2=C1 LRTIKMXIKAOCDM-UHFFFAOYSA-N 0.000 description 1
- ZKGSVVHFMZASJS-UHFFFAOYSA-N 6-methyl-1h-indole-2-carboxylic acid Chemical compound CC1=CC=C2C=C(C(O)=O)NC2=C1 ZKGSVVHFMZASJS-UHFFFAOYSA-N 0.000 description 1
- NVKAHBFPKVINGE-UHFFFAOYSA-N 7-chloro-1h-indole-2-carboxylic acid Chemical compound C1=CC(Cl)=C2NC(C(=O)O)=CC2=C1 NVKAHBFPKVINGE-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- GFHHIWFKWFBNRU-UHFFFAOYSA-N 9h-carbazole-1-carboxamide Chemical class C12=CC=CC=C2NC2=C1C=CC=C2C(=O)N GFHHIWFKWFBNRU-UHFFFAOYSA-N 0.000 description 1
- 229940124321 AIDS medicine Drugs 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- AXRYRYVKAWYZBR-UHFFFAOYSA-N Atazanavir Natural products C=1C=C(C=2N=CC=CC=2)C=CC=1CN(NC(=O)C(NC(=O)OC)C(C)(C)C)CC(O)C(NC(=O)C(NC(=O)OC)C(C)(C)C)CC1=CC=CC=C1 AXRYRYVKAWYZBR-UHFFFAOYSA-N 0.000 description 1
- 229940124291 BTK inhibitor Drugs 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- CCNGUBMPKAMAPM-VDISTLRHSA-N C(#N)C1=C2C=C(NC2=CC(=C1)C#N)C(=O)N[C@@H]1CC[C@@H](CC1)C Chemical compound C(#N)C1=C2C=C(NC2=CC(=C1)C#N)C(=O)N[C@@H]1CC[C@@H](CC1)C CCNGUBMPKAMAPM-VDISTLRHSA-N 0.000 description 1
- WKUARDIMLGEXDQ-WKILWMFISA-N CC(C)[C@H](CC1)CC[C@@H]1N1C2=CC(C)=CC(C)=C2C=C1C(N)=O Chemical compound CC(C)[C@H](CC1)CC[C@@H]1N1C2=CC(C)=CC(C)=C2C=C1C(N)=O WKUARDIMLGEXDQ-WKILWMFISA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 229940021995 DNA vaccine Drugs 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- XXRCUYVCPSWGCC-UHFFFAOYSA-N Ethyl pyruvate Chemical compound CCOC(=O)C(C)=O XXRCUYVCPSWGCC-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 238000006783 Fischer indole synthesis reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 102100033096 Interleukin-17D Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010066979 Interleukin-27 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102000000704 Interleukin-7 Human genes 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010062207 Mycobacterial infection Diseases 0.000 description 1
- 241001467553 Mycobacterium africanum Species 0.000 description 1
- 241000186367 Mycobacterium avium Species 0.000 description 1
- 241000186366 Mycobacterium bovis Species 0.000 description 1
- 241000187919 Mycobacterium microti Species 0.000 description 1
- 101000944608 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) Chaperonin GroEL 2 Proteins 0.000 description 1
- 241001646725 Mycobacterium tuberculosis H37Rv Species 0.000 description 1
- 108700035964 Mycobacterium tuberculosis HsaD Proteins 0.000 description 1
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- 229940122055 Serine protease inhibitor Drugs 0.000 description 1
- 101710102218 Serine protease inhibitor Proteins 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- KGTSLTYUUFWZNW-PPJQWWMSSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate pyridine-4-carbohydrazide Chemical compound NNC(=O)c1ccncc1.CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C KGTSLTYUUFWZNW-PPJQWWMSSA-N 0.000 description 1
- GLWHPRRGGYLLRV-XLPZGREQSA-N [[(2s,3s,5r)-3-azido-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](N=[N+]=[N-])C1 GLWHPRRGGYLLRV-XLPZGREQSA-N 0.000 description 1
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 1
- 229960004748 abacavir Drugs 0.000 description 1
- WMHSRBZIJNQHKT-FFKFEZPRSA-N abacavir sulfate Chemical compound OS(O)(=O)=O.C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1.C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 WMHSRBZIJNQHKT-FFKFEZPRSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000370 acceptor Substances 0.000 description 1
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000036981 active tuberculosis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001355 anti-mycobacterial effect Effects 0.000 description 1
- 230000002365 anti-tubercular Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229940054051 antipsychotic indole derivative Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 229960003277 atazanavir Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- DCBDOYDVQJVXOH-UHFFFAOYSA-N azane;1h-indole Chemical compound N.C1=CC=C2NC=CC2=C1 DCBDOYDVQJVXOH-UHFFFAOYSA-N 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- PMDQGYMGQKTCSX-HQROKSDRSA-L calcium;[(2r,3s)-1-[(4-aminophenyl)sulfonyl-(2-methylpropyl)amino]-3-[[(3s)-oxolan-3-yl]oxycarbonylamino]-4-phenylbutan-2-yl] phosphate Chemical compound [Ca+2].C([C@@H]([C@H](OP([O-])([O-])=O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 PMDQGYMGQKTCSX-HQROKSDRSA-L 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- 239000013000 chemical inhibitor Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- 125000004773 chlorofluoromethyl group Chemical group [H]C(F)(Cl)* 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 229940014461 combivir Drugs 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 238000010205 computational analysis Methods 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- VXVVUHQULXCUPF-UHFFFAOYSA-N cycloheptanamine Chemical compound NC1CCCCCC1 VXVVUHQULXCUPF-UHFFFAOYSA-N 0.000 description 1
- 150000001934 cyclohexanes Chemical class 0.000 description 1
- AVKNGPAMCBSNSO-UHFFFAOYSA-N cyclohexylmethanamine Chemical compound NCC1CCCCC1 AVKNGPAMCBSNSO-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229960005107 darunavir Drugs 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- XDAOLTSRNUSPPH-XMMPIXPASA-N delamanid Chemical compound C([C@]1(C)OC2=NC(=CN2C1)[N+]([O-])=O)OC(C=C1)=CC=C1N(CC1)CCC1OC1=CC=C(OC(F)(F)F)C=C1 XDAOLTSRNUSPPH-XMMPIXPASA-N 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- CNXMDTWQWLGCPE-UHFFFAOYSA-N ditert-butyl-(2-phenylphenyl)phosphane Chemical compound CC(C)(C)P(C(C)(C)C)C1=CC=CC=C1C1=CC=CC=C1 CNXMDTWQWLGCPE-UHFFFAOYSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 208000015355 drug-resistant tuberculosis Diseases 0.000 description 1
- 229960003804 efavirenz Drugs 0.000 description 1
- 229960002062 enfuvirtide Drugs 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LHWWETDBWVTKJO-UHFFFAOYSA-N et3n triethylamine Chemical compound CCN(CC)CC.CCN(CC)CC LHWWETDBWVTKJO-UHFFFAOYSA-N 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- QIGMOXZGOZDGLW-UHFFFAOYSA-N ethyl 4,6-dicyano-1h-indole-2-carboxylate Chemical compound C1=C(C#N)C=C2NC(C(=O)OCC)=CC2=C1C#N QIGMOXZGOZDGLW-UHFFFAOYSA-N 0.000 description 1
- KNPDUPLMXYEJAU-UHFFFAOYSA-N ethyl 4-bromo-1h-indole-2-carboxylate Chemical compound C1=CC=C2NC(C(=O)OCC)=CC2=C1Br KNPDUPLMXYEJAU-UHFFFAOYSA-N 0.000 description 1
- WNNIWIDWIHSDHK-UHFFFAOYSA-N ethyl 4-cyano-1h-indole-2-carboxylate Chemical compound C1=CC=C2NC(C(=O)OCC)=CC2=C1C#N WNNIWIDWIHSDHK-UHFFFAOYSA-N 0.000 description 1
- 229940117360 ethyl pyruvate Drugs 0.000 description 1
- 229960002049 etravirine Drugs 0.000 description 1
- 238000000105 evaporative light scattering detection Methods 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 229960003142 fosamprenavir Drugs 0.000 description 1
- MLBVMOWEQCZNCC-OEMFJLHTSA-N fosamprenavir Chemical compound C([C@@H]([C@H](OP(O)(O)=O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 MLBVMOWEQCZNCC-OEMFJLHTSA-N 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229940099052 fuzeon Drugs 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 150000005232 imidazopyridines Chemical class 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940124524 integrase inhibitor Drugs 0.000 description 1
- 239000002850 integrase inhibitor Substances 0.000 description 1
- 229940115474 intelence Drugs 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 229940100994 interleukin-7 Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- PGJLOGNVZGRMGX-UHFFFAOYSA-L iron(2+);trifluoromethanesulfonate Chemical compound [Fe+2].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F PGJLOGNVZGRMGX-UHFFFAOYSA-L 0.000 description 1
- 229940111682 isentress Drugs 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 229940113354 lexiva Drugs 0.000 description 1
- 125000005647 linker group Chemical group 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- NCBZRJODKRCREW-UHFFFAOYSA-N m-anisidine Chemical compound COC1=CC=CC(N)=C1 NCBZRJODKRCREW-UHFFFAOYSA-N 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 229960004710 maraviroc Drugs 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 208000027531 mycobacterial infectious disease Diseases 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- MGNPLIACIXIYJE-UHFFFAOYSA-N n-fluoroaniline Chemical compound FNC1=CC=CC=C1 MGNPLIACIXIYJE-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229950006327 napsilate Drugs 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 230000024121 nodulation Effects 0.000 description 1
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 description 1
- 229940072250 norvir Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- BHAAPTBBJKJZER-UHFFFAOYSA-N p-anisidine Chemical compound COC1=CC=C(N)C=C1 BHAAPTBBJKJZER-UHFFFAOYSA-N 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229960005141 piperazine Drugs 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 229940068586 prezista Drugs 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 150000003233 pyrroles Chemical class 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 229960004742 raltegravir Drugs 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 229940107904 reyataz Drugs 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- MOODSJOROWROTO-UHFFFAOYSA-N salicylsulfuric acid Chemical compound OC(=O)C1=CC=CC=C1OS(O)(=O)=O MOODSJOROWROTO-UHFFFAOYSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940031307 selzentry Drugs 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- WGRULTCAYDOGQK-UHFFFAOYSA-M sodium;sodium;hydroxide Chemical compound [OH-].[Na].[Na+] WGRULTCAYDOGQK-UHFFFAOYSA-M 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- XKPDOWURXRJLMO-UHFFFAOYSA-N spiro[2.5]octan-6-amine Chemical compound C1CC(N)CCC11CC1 XKPDOWURXRJLMO-UHFFFAOYSA-N 0.000 description 1
- RYAOBOBRKJJPEE-UHFFFAOYSA-N spiro[3.5]nonan-7-amine Chemical compound C1CC(N)CCC11CCC1 RYAOBOBRKJJPEE-UHFFFAOYSA-N 0.000 description 1
- QPIGFMXNPDOLDK-UHFFFAOYSA-N spiro[4.5]decan-8-amine Chemical compound C1CC(N)CCC11CCCC1 QPIGFMXNPDOLDK-UHFFFAOYSA-N 0.000 description 1
- BAERJJQGHJOXHR-UHFFFAOYSA-N spiro[5.5]undecan-3-amine Chemical compound C1CC(N)CCC11CCCCC1 BAERJJQGHJOXHR-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000001119 stannous chloride Substances 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229940071103 sulfosalicylate Drugs 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229940054565 sustiva Drugs 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- PHCBRBWANGJMHS-UHFFFAOYSA-J tetrasodium;disulfate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O PHCBRBWANGJMHS-UHFFFAOYSA-J 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 229940008349 truvada Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000012070 whole genome sequencing analysis Methods 0.000 description 1
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 1
- 229940052255 ziagen Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261698033P | 2012-09-07 | 2012-09-07 | |
| US201261698033P | 2012-09-07 | ||
| PCT/IB2013/058318 WO2014037900A1 (en) | 2012-09-07 | 2013-09-05 | Indole carboxamide derivatives and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2660210T3 true ES2660210T3 (es) | 2018-03-21 |
Family
ID=49585451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13792084.9T Active ES2660210T3 (es) | 2012-09-07 | 2013-09-05 | Derivados de indolcarboxamida y usos de los mismos |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US9447039B2 (enExample) |
| EP (1) | EP2892880B1 (enExample) |
| JP (1) | JP6223452B2 (enExample) |
| KR (1) | KR20150048759A (enExample) |
| CN (1) | CN104603106B (enExample) |
| BR (1) | BR112015004666B1 (enExample) |
| CA (1) | CA2881351A1 (enExample) |
| EA (1) | EA028093B1 (enExample) |
| ES (1) | ES2660210T3 (enExample) |
| IN (1) | IN2015DN01163A (enExample) |
| WO (1) | WO2014037900A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10167257B2 (en) | 2014-04-04 | 2019-01-01 | Iomet Pharma Ltd. | Indole derivatives for use in medicine |
| WO2015164482A1 (en) * | 2014-04-22 | 2015-10-29 | The Johns Hopkins University | Inhibitors of drug-resistant mycobacterium tuberculosis |
| PE20190710A1 (es) * | 2014-10-24 | 2019-05-17 | Bristol Myers Squibb Co | Compuestos de indol carboxamida utiles como inhibidores de cinasas |
| EP3444031B1 (en) * | 2016-04-15 | 2022-11-30 | CE Pharm Co.,Ltd | Heterocyclic carboxylic acid amide ligand and applications thereof in copper catalyzed coupling reaction of aryl halogeno substitute |
| CN110305798B (zh) * | 2016-06-15 | 2021-11-19 | 中国医学科学院医药生物技术研究所 | 一株曲霉菌的用途及由该曲霉菌制备的化合物及其用途 |
| US10383848B2 (en) * | 2016-08-04 | 2019-08-20 | Creighton University | Indole-based therapeutics |
| US10858319B2 (en) | 2016-10-03 | 2020-12-08 | Iomet Pharma Ltd. | Indole derivatives for use in medicine |
| SG11201908351TA (en) | 2017-03-10 | 2019-10-30 | Edmond J Lavoie | Indole derivatives as efflux pump inhibitors |
| US11938114B2 (en) | 2017-03-10 | 2024-03-26 | Rutgers, The State University Of New Jersey | Bacterial efflux pump inhibitors |
| WO2018165612A1 (en) | 2017-03-10 | 2018-09-13 | Rutgers, The State University Of New Jersey | Bacterial efflux pump inhibitors |
| EP3630109A4 (en) * | 2017-05-26 | 2021-03-17 | Rutgers, the State University of New Jersey | BACTERIAL EFFLUX PUMP INHIBITORS |
| WO2019005841A1 (en) * | 2017-06-26 | 2019-01-03 | Rutgers, The State University Of New Jersey | THERAPEUTIC COMPOUNDS AND METHODS FOR TREATING INFECTION |
| US11718633B2 (en) | 2018-05-17 | 2023-08-08 | Council Of Scientific And Industrial Research | Indole compounds, process for the preparation and use thereof |
| KR102219563B1 (ko) * | 2019-02-15 | 2021-02-24 | 에스티팜 주식회사 | 페나진 유도체 제조를 위한 중간체 및 그의 제조방법 |
| CN110577483B (zh) * | 2019-09-26 | 2020-05-12 | 海南医学院 | 一种3,3-二取代-2-吲哚酮的绿色合成方法 |
| EP4034103A4 (en) * | 2019-09-26 | 2023-10-25 | The Global Alliance for TB Drug Development, Inc. | Indole carboxamide compounds and use thereof for the treatment of mycobacterial infections |
| CA3151408A1 (en) * | 2019-09-26 | 2021-04-01 | The Global Alliance For Tb Drug Development, Inc. | Azaindole carboxamide compounds for the treatment of mycobacterial infections |
| US20220396586A1 (en) * | 2019-09-26 | 2022-12-15 | The Global Alliance For Tb Drug Development, Inc. | Thiazole carboxamide compounds and use thereof for the treatment of mycobacterial infections |
| RU2767542C1 (ru) * | 2021-05-24 | 2022-03-17 | Федеральное государственное автономное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" (ПГНИУ) | Противотуберкулезное средство на основе 4-((гет)ароил)-3- гидрокси-1-(2-гидроксифенил)-5-(фенилтио)-1,5-дигидро-2Н-пиррол-2-онов |
| CN115583908B (zh) * | 2021-07-05 | 2024-08-06 | 西北农林科技大学 | 一种吲哚甲酰胺类化合物及其制备方法和用途 |
| WO2023287704A1 (en) * | 2021-07-12 | 2023-01-19 | Nido Biosciences, Inc. | Bicyclic compounds as androgen receptor modulators |
| KR20250107282A (ko) * | 2022-12-02 | 2025-07-11 | 머크 샤프 앤드 돔 엘엘씨 | 신규 디아실글리세리드 o-아실트랜스퍼라제 2 억제제로서의 융합된 아졸 유도체의 제조 |
| CN118724763B (zh) * | 2024-09-02 | 2024-12-06 | 辽宁龙田化工科技有限公司 | 一种4-甲基苯磺酰氯合成方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US883049A (en) * | 1907-09-12 | 1908-03-24 | John W Piver | Tongue-and-groove joint for flooring. |
| FR2705095B1 (fr) * | 1993-05-12 | 1995-06-23 | Adir | Nouveaux indoles substitués, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. |
| HU227197B1 (en) * | 2000-10-24 | 2010-10-28 | Richter Gedeon Nyrt | Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them |
| WO2003000657A1 (en) | 2001-06-20 | 2003-01-03 | Daiichi Pharmaceutical Co., Ltd. | Diamine derivatives |
| WO2003035621A1 (en) | 2001-10-22 | 2003-05-01 | The Research Foundation Of State University Of New York | Protein kinase and phosphatase inhibitors, methods for designing them, and methods of using them |
| HUP0402344A2 (hu) | 2001-12-04 | 2005-02-28 | F. Hoffmann-La Roche Ag | Helyettesített 2-amino-cikloalkán-karboxamidok, felhasználásuk cisztein-proteáz-inhibitorként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények |
| US6759428B2 (en) | 2001-12-04 | 2004-07-06 | Roche Palo Alto Llc | Indole nitriles |
| WO2003091213A1 (en) * | 2002-04-25 | 2003-11-06 | Yamanouchi Pharmaceutical Co., Ltd. | Novel amide derivatives or salts thereof |
| JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
| GB0428173D0 (en) * | 2004-12-23 | 2005-01-26 | Astrazeneca Ab | Compounds |
| US7825154B2 (en) * | 2005-08-12 | 2010-11-02 | The United States Of America As Represented By The Secretary Of The Army | Small molecule inhibitors of botulinum neurotoxins |
| BRPI0710527B8 (pt) | 2006-04-04 | 2021-05-25 | Fibrogen Inc | compostos de pirrolo- e tiazolo-piridina e composição farmacêutica que os compreende |
| WO2009063495A2 (en) | 2007-09-20 | 2009-05-22 | Cadila Healthcare Limited | Substituted indole and its derivatives as cannabinoid modulators |
| US8084620B2 (en) * | 2008-12-19 | 2011-12-27 | Bristol-Myers Squibb Company | Carbazole carboxamide compounds useful as kinase inhibitors |
| CN104856991A (zh) | 2009-02-27 | 2015-08-26 | 西佳技术公司 | 用于治疗和预防登革热病毒感染的噻吩并吡啶衍生物 |
| TW201107330A (en) | 2009-07-31 | 2011-03-01 | Biocryst Pharm Inc | Heterocyclic compounds as janus kinase inhibitors |
| CA2781888C (en) | 2009-12-11 | 2019-06-18 | Nono Inc. | Agents and methods for treating ischemic and other diseases |
| JP2012107001A (ja) | 2010-10-22 | 2012-06-07 | Shionogi & Co Ltd | インドールアミド化合物を含有する医薬 |
| US9200046B2 (en) * | 2011-06-29 | 2015-12-01 | Cornell University | Reporter system for high throughput screening of compounds and uses thereof |
-
2013
- 2013-09-05 ES ES13792084.9T patent/ES2660210T3/es active Active
- 2013-09-05 CN CN201380046508.9A patent/CN104603106B/zh not_active Expired - Fee Related
- 2013-09-05 EA EA201590504A patent/EA028093B1/ru not_active IP Right Cessation
- 2013-09-05 EP EP13792084.9A patent/EP2892880B1/en not_active Not-in-force
- 2013-09-05 BR BR112015004666-5A patent/BR112015004666B1/pt not_active IP Right Cessation
- 2013-09-05 WO PCT/IB2013/058318 patent/WO2014037900A1/en not_active Ceased
- 2013-09-05 CA CA2881351A patent/CA2881351A1/en not_active Abandoned
- 2013-09-05 JP JP2015530536A patent/JP6223452B2/ja not_active Expired - Fee Related
- 2013-09-05 US US14/420,074 patent/US9447039B2/en active Active
- 2013-09-05 KR KR1020157005663A patent/KR20150048759A/ko not_active Withdrawn
-
2015
- 2015-02-12 IN IN1163DEN2015 patent/IN2015DN01163A/en unknown
-
2016
- 2016-08-19 US US15/242,160 patent/US20160355477A1/en not_active Abandoned
-
2020
- 2020-06-12 US US16/899,931 patent/US20210032202A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20150175539A1 (en) | 2015-06-25 |
| US9447039B2 (en) | 2016-09-20 |
| WO2014037900A1 (en) | 2014-03-13 |
| BR112015004666A2 (pt) | 2017-07-04 |
| US20160355477A1 (en) | 2016-12-08 |
| AU2013311235A1 (en) | 2015-02-26 |
| CA2881351A1 (en) | 2014-03-13 |
| CN104603106A (zh) | 2015-05-06 |
| JP6223452B2 (ja) | 2017-11-01 |
| IN2015DN01163A (enExample) | 2015-06-26 |
| EP2892880B1 (en) | 2017-11-22 |
| BR112015004666B1 (pt) | 2022-04-26 |
| CN104603106B (zh) | 2017-05-10 |
| US20210032202A1 (en) | 2021-02-04 |
| JP2015527388A (ja) | 2015-09-17 |
| EA201590504A1 (ru) | 2015-07-30 |
| EP2892880A1 (en) | 2015-07-15 |
| KR20150048759A (ko) | 2015-05-07 |
| EA028093B1 (ru) | 2017-10-31 |
| AU2013311235B2 (en) | 2016-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2660210T3 (es) | Derivados de indolcarboxamida y usos de los mismos | |
| TWI808067B (zh) | 作為ehmt2抑制劑之胺取代的雜環化合物及其使用方法 | |
| RU2734760C2 (ru) | Противоинфекционные соединения | |
| JP2018522866A (ja) | ４，６−ピリミジニレン誘導体およびこれらの使用 | |
| WO2014137723A1 (en) | Compounds inhibiting leucine-rich repeat kinase enzyme activity | |
| JP2018522867A (ja) | 縮合二環式ピリミジン誘導体およびこれらの使用 | |
| BR112013023266B1 (pt) | inibidores da girase tricíclicos | |
| CN104520291A (zh) | 用于调节egfr活性的化合物和组合物 | |
| JP2020524148A (ja) | 置換５−シアノインドール化合物及びその使用 | |
| CN109790123B (zh) | 新型衣壳蛋白装配抑制剂 | |
| CN103102349B (zh) | 蛋白激酶抑制剂及其组合物和用途 | |
| US20150183802A1 (en) | Tricyclic sulfonamide derivatives | |
| CA3051354A1 (en) | Tetrahydroquinoline substituted hydroxamic acids as selective histone deacetylase 6 inhibitors | |
| US20230257351A1 (en) | Substituted n-phenylacetamides having p2x4 receptor antagonistic activity | |
| US9546138B2 (en) | Pyridone derivatives and uses thereof in the treatment of tuberculosis | |
| AU2013311235B9 (en) | Indole carboxamide derivatives and uses thereof | |
| BR112018072255B1 (pt) | Azasteroides para tratamento de tuberculose | |
| TW202229277A (zh) | 用於治療隱孢子蟲病之化合物及組成物 | |
| CN103814025A (zh) | 可用作胆碱激酶抑制剂的化合物 | |
| US11518744B2 (en) | Benzamide compound and preparation method, use, and pharmaceutical composition thereof | |
| CN107118209A (zh) | 吡啶骈[3,4-b]吲哚脲类化合物及其作为IDO抑制剂的用途 | |
| EA050101B1 (ru) | СОЕДИНЕНИЯ, ТАРГЕТИРУЮЩИЕ МУТАНТ р53 | |
| TW201028416A (en) | 2-aza-bicyclo[2.2.2]octane compounds and uses thereof |